- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06076486
A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain
October 6, 2023 updated by: Nanjing Chia-tai Tianqing Pharmaceutical
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Elagolix Tablets in Patients With Moderate or Severe Endometriosis-associated Pain
This is a phase 3, multicenter, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of elagolix tablets versus placebo in premenopausal women with moderate or severe endometriosis-associated pain.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
330
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yingfang Zhou
- Phone Number: 010-83572211
- Email: Zhouyf8853@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Recruiting
- Peking University first hospital
-
Contact:
- Yingfang Zhou
- Phone Number: 010-83572211
- Email: Zhouyf8853@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent.
- Diagnosis of endometriosis by pathological diagnosis or surgery within 10 years prior to screening by laparoscopy or exploratory laparotomy; or diagnosis of endometriosis based on clinical presentation of endometriosis in combination with previous imaging studies according to Endometriosis Diagnosis and Treatment Guidelines (Third Edition).
- Premenopausal female aged 18 and 49 years (both inclusive) with one complete menstruation prior to screening record in the diary for at least 35 days and at least one complete menstrual cycle before the first dosing.
- Agree to take only protocol-specified permitted rescue analgesic medications during the screening and treatment Periods.
- Cervical smear is normal or abnormal without clinical significance (acceptance of normal cervical smear within 6 months prior to screening; or participant is virgin and decides not to take cervical smear); ASCUS may be combined with HPV testing. ASCUS participants may be included if they are negative for high-risk HPV.
- Agree to use non-hormonal contraception from signing the informed consent through 1 month after last dosing.
Exclusion Criteria:
- Subjects with a history of sensitivity to elagolix or excipients; or with a known history of serious, life-threatening or significant allergy to any drug.
- Previous non-responders to GnRH agonist or GnRH antagonist therapy as judged by the investigator.
- Subjects with a history of previous or existing osteoporosis or other metabolic bone disease; or previous abnormal clinically significant hypocalcemia, hypophosphatemia or hyperphosphatemia; or DXA Z score (subjects < 40 years old) or T score (subjects ≥ 40 years old) of lumbar spine (L1-L4), femoral neck or total hip BMD is < -2.0;
- Subjects with unstable diseases (such as poorly controlled diabetes, poorly controlled hypertension, poorly controlled seizures, unstable angina pectoris, inflammatory bowel disease, hyperprolactinemia, malignant tumors (except basal cell carcinoma of the skin) or severe infection, etc.) unuitable for the study at screening as judged by the investigators;
- Subjects with a history of hysterectomy, oophorectomy, or surgery affecting drug absorption; or those who plan to undergo the above surgery during the trial;
- Subjects with a history of major depressive disorder or post-traumatic stress disorder within 2 years prior to screening or other major psychiatric disorder at any time (e.g., schizophrenia, bipolar disorder); or history of suicidal behavior or suicidality; or suicidality as judged by the investigators;
- Subjects with undiagnosed vaginal and/or uterine bleeding within 3 months prior to screening;
- Subjects with other chronic pain syndromes requiring chronic analgesia or other long-term treatment that would be expected to interfere with the assessment of endometriosis-related pain;
- Subjects with a history of drug or alcohol abuse within 6 months prior to screening;
- Subjects aged ≥ 40 years with abnormal results of breast ultrasonography during the screening period or within 1 year prior to screening (BI-RADS classification grade 4 and above);
- Clinically significant gynecological conditions (e.g., any non-malignant cyst > 6 cm, or malignant cyst) by TVU or transrectal ultrasound or transabdominal ultrasound at screening;
- Subjects with hepatitis B [HbsAg is positive and detection of HBV-DNA indicates viral replication], hepatitis C [HCV antibody is positive and detection of HCV-RNA indicates viral replication], positive syphilis (except specific antibody detection positive, non-specific antibody detection negative and confirmed as inactive infection in combination with clinical judgment), known HIV positive history or HIV positive;
- Subjects with moderate/severe liver injury caused by previous diseases, or AST or ALT or bilirubin ≥ 2 × ULN at screening;
- Subjects requiring the use of a prohibited long-acting anesthetic or immediate-release anesthetic for more than 2 consecutive weeks for the treatment of endometriosis-related pain within 6 months prior to screening;
- Participation in any other interventional clinical trial (including drug and device clinical trials) within 1 month prior to screening;
- Use of any systemic corticosteroids for more than 2 weeks within 3 months prior to screening or likely to require such therapy during the study (topical, inhaled, or nasal corticosteroids are allowed);
- Use of GnRH agonists or GnRH antagonists (including participation in clinical trails of elagolix) within 6 months prior to screening; use of medroxyprogesterone acetate, danazol, aromatase inhibitors within 3 months prior to screening; use of oral contraceptives, or any hormonal treatment for endometriosis within 2 months prior to screening; use of Chinese herbal medicine for endometriosis treatment or symptom relief within 1 month prior to screening;
- Subjects with IUD or subcutaneous contraceptive implants (the IUD or subcutaneous contraceptive implants removed more than 30 days prior to screening is allowed);
- Subjects taking moderate or strong CYP450 3A inducers or OATP1B1 inhibitors within 1 month prior to the first dosing;
- Pregnant or lactating women; or plan to have children during the trial (from signing the informed consent form to 3 months after using the study drug); or < 6 months after delivery; or < 3 months after abortion; or have a positive pregnancy test result during the screening period or on the day of randomization;
- Subjects with increasing risk associated with the study, interference with the interpretation of study results, or inappropriate as judged by the investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Elagolix 200 mg BID
Participants received elagolix 200 mg tablets twice a day (BID)
|
Elagolix 200 mg tablets administered orally BID
|
Placebo Comparator: Elagolix placebo
Participants received elagolix placebo twice a day (BID)
|
Elagolix placebo administered orally BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of responders of dysmenorrhea (DYS) at week 12
Time Frame: 12 weeks
|
The responder was defined as reaching a pre-defined threshold.
|
12 weeks
|
Percentage of responders of Non-Menstrual Pelvic Pain (NMPP) at week 12
Time Frame: 12 weeks
|
The responder was defined as reaching a pre-defined threshold.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in DYS
Time Frame: Through study completion, an average of 24 weeks
|
The DYS pain scale s range from 0 (none) to 3 (severe).
|
Through study completion, an average of 24 weeks
|
Change from baseline in NMPP
Time Frame: Through study completion, an average of 24 weeks
|
The NMPP pain scales range from 0 (none) to 3 (severe).
|
Through study completion, an average of 24 weeks
|
Change from baseline in Dyspareunia (DYSP)
Time Frame: Through study completion, an average of 24 weeks
|
The DYSP pain scales range from 0 (none) to 3 (severe).
|
Through study completion, an average of 24 weeks
|
Change from baseline in Numeric Rating Scale (NRS) scores
Time Frame: Through study completion, an average of 24 weeks
|
The NRS pain scores ranges 0 (none) to 10 (worst pain ever).
|
Through study completion, an average of 24 weeks
|
Change from baseline in rescue analgesic use
Time Frame: Through study completion, an average of 24 weeks
|
Use of rescue analgesic medications taken for endometriosis-associated pain was recorded by the subject daily as the total number of pills/tablets of each type taken within a 24-hour period.
|
Through study completion, an average of 24 weeks
|
Percentage of participants with a Patient Global Impression of Change (PGIC) response
Time Frame: Through study completion, an average of 24 weeks
|
PGIC response was defined as very much improved and much improved selected by the subject to assess the change in endometriosis-associated pain since the initiation of study drug.
|
Through study completion, an average of 24 weeks
|
Safety Specifications in the Treatment Period
Time Frame: Through study completion, an average of 24 weeks
|
AEs and SAEs occurred during the treatment period.
|
Through study completion, an average of 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yingfang Zhou, Peking University first hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 14, 2023
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
September 13, 2023
First Submitted That Met QC Criteria
October 6, 2023
First Posted (Estimated)
October 10, 2023
Study Record Updates
Last Update Posted (Estimated)
October 10, 2023
Last Update Submitted That Met QC Criteria
October 6, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALGKNP2022-III
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometriosis
-
Fabio BarraCompletedEndometriosis | Endometriosis, Rectum | Endometriosis of Vagina | Endometriosis Rectovaginal Septum | Endometriosis Pelvic | Endometriosis of ColonItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis | Bowel Endometriosis | Endometriosis, Rectum | Endometriosis ColonItaly
-
BioGene Pharmaceutical Ltd.WithdrawnSafety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis ExternaSwitzerland
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedEndometriosis | Endometriosis-related Pain | Endometriosis Thoracic | Endometriosis of Lung | Endometriosis of PleuraItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis, Rectum | Endometriosis, SigmoidItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownBowel Endometriosis | Endometriosis, RectumItaly
-
Ospedale Policlinico San MartinoActive, not recruitingEndometriosis, Rectum | Endometriosis of ColonItaly
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
-
Semmelweis UniversityUniversity of PecsNot yet recruitingEndometriosis | Endometriosis Ovary | Endometriosis Rectovaginal Septum
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
Clinical Trials on Elagolix
-
AbbVie (prior sponsor, Abbott)Neurocrine BiosciencesCompletedFolliculogenesisUnited States, Puerto Rico
-
Qilu Pharmaceutical (Hainan) Co., Ltd.Recruiting
-
AbbVieCompletedUterine FibroidsUnited States, Puerto Rico
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
BayerTerminatedEndometriosisSpain, Belgium, United States, Germany, Austria, Japan, Canada, Hungary, Bulgaria, Italy, China, Czechia, Finland, Norway, Poland, Slovakia, Estonia, Greece, Latvia, Lithuania
-
AbbVieActive, not recruitingUterine Fibroids | Heavy Menstrual BleedingUnited States, Puerto Rico
-
AbbVie (prior sponsor, Abbott)Completed
-
AbbVieCompletedEndometriosis, Pain
-
AbbVieCompletedPolycystic Ovary SyndromeUnited States, Puerto Rico